Trading Report: Today, Amica Retiree Medical Trust decides to keep it stake in C.R. Bard Inc. (BCR) to the level of $172,000

Today, Amica Retiree Medical Trust decides to keep it stake in C.R. Bard Inc. (BCR) to the level of $172,000

Amica Retiree Medical Trust held its stake in shares of C.R. Bard Inc. (NYSE:BCR) during the third quarter, Holdings Channel reports. The institutional investor owned 768 shares of the company’s stock at the end of the third quarter. Amica Retiree Medical Trust’s holdings in C.R. Bard were worth $172,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Cypress Capital Group raised its stake in shares of C.R. Bard by 0.3% in the first quarter. Cypress Capital Group now owns 2,392 shares of the company’s stock worth $485,000 after buying an additional 7 shares during the last quarter. Foster & Motley Inc. raised its stake in shares of C.R. Bard by 0.3% in the second quarter. Foster & Motley Inc. now owns 3,851 shares of the company’s stock worth $906,000 after buying an additional 11 shares during the last quarter. Cleararc Capital Inc. raised its stake in shares of C.R. Bard by 0.9% in the second quarter. Cleararc Capital Inc. now owns 1,795 shares of the company’s stock worth $422,000 after buying an additional 16 shares during the last quarter. Gateway Investment Advisers LLC raised its stake in shares of C.R. Bard by 0.3% in the third quarter. Gateway Investment Advisers LLC now owns 5,073 shares of the company’s stock worth $1,138,000 after buying an additional 17 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its stake in shares of C.R. Bard by 1.3% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 1,863 shares of the company’s stock worth $394,000 after buying an additional 24 shares during the last quarter. Institutional investors own 88.17% of the company’s stock.

C.R. Bard Inc. (NYSE:BCR) traded up 1.24% during midday trading on Friday, reaching $212.61. The company’s stock had a trading volume of 272,706 shares. The firm has a market cap of $15.63 billion, a P/E ratio of 32.11 and a beta of 0.67. C.R. Bard Inc. has a 52-week low of $172.21 and a 52-week high of $239.43. The firm has a 50 day moving average of $217.17 and a 200 day moving average of $222.51.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Tuesday, October 25th. The company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.55 by $0.09. The company earned $941.90 million during the quarter, compared to analysts’ expectations of $931.66 million. C.R. Bard had a return on equity of 48.13% and a net margin of 14.05%. The business’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.28 earnings per share. Analysts anticipate that C.R. Bard Inc. will post $10.26 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, November 4th. Stockholders of record on Monday, October 24th were paid a $0.26 dividend. The ex-dividend date of this dividend was Thursday, October 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.49%. C.R. Bard’s payout ratio is 15.48%.

BCR has been the subject of a number of research reports. Leerink Swann reiterated a “market perform” rating and issued a $233.00 price objective (down from $240.00) on shares of C.R. Bard in a research report on Thursday, July 28th. Morgan Stanley reiterated a “hold” rating and issued a $240.00 price objective on shares of C.R. Bard in a research report on Thursday, July 28th. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. Evercore ISI began coverage on C.R. Bard in a report on Thursday, September 15th. They set a “buy” rating and a $235.00 target price on the stock. Finally, Wells Fargo & Co. upgraded C.R. Bard from a “market perform” rating to an “outperform” rating in a report on Friday, September 16th. Nine equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $233.07.

In related news, VP Betty D. Larson sold 4,032 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $225.33, for a total transaction of $908,530.56. Following the completion of the sale, the vice president now owns 10,298 shares of the company’s stock, valued at $2,320,448.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher S. Holland sold 5,724 shares of the firm’s stock in a transaction that occurred on Friday, October 28th. The stock was sold at an average price of $211.12, for a total value of $1,208,450.88. The disclosure for this sale can be found here. 0.97% of the stock is owned by insiders.

About C.R. Bard

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

Related posts

Leave a Comment